Cited 3 time in
Proteinase K-containing Lipid Nanoparticles for Therapeutic Delivery of siRNA LOR-1284
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Dong Chul | - |
| dc.contributor.author | Cho, Young Ah | - |
| dc.contributor.author | Li, Hong | - |
| dc.contributor.author | Yung, Bryant C. | - |
| dc.contributor.author | Lee, Robert J. | - |
| dc.date.accessioned | 2022-12-26T23:04:35Z | - |
| dc.date.available | 2022-12-26T23:04:35Z | - |
| dc.date.issued | 2014-07 | - |
| dc.identifier.issn | 0250-7005 | - |
| dc.identifier.issn | 1791-7530 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/18916 | - |
| dc.description.abstract | Background: The objective of the present study was to develop an efficient delivery vehicle for siRNA LOR-1284 through incorporation of proteinase K (PrK) as a means of preventing siRNA degradation by serum nucleases. Lipid nanoparticle-PrK-siRNA (LN-PrK-siRNA) complexes were synthesized and characterized. Materials and Methods: siRNA complexed with PrK and liposomes composed of dimethyldioctadecyl ammonium bromide/cholesterol/Tween 80 (60:35:5 molar ratio) were investigated for down-regulation of R2 mRNA activity in KB human carcinoma cells. Results: Treatment with LN-PrK-siRNA (30:0.3:1 molar ratio) significantly reduced levels of R2 mRNA compared to siRNA-liposomes without PrK in serum-containing medium. LN-PrK-siRNA complexes showed increased stability in serum and reduced toxicity in KB cells relative to LN-siRNA complexes. Conclusion: LN-PrK-siRNA complexes are promising delivery vehicles for siRNA. | - |
| dc.format.extent | 5 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | INT INST ANTICANCER RESEARCH | - |
| dc.title | Proteinase K-containing Lipid Nanoparticles for Therapeutic Delivery of siRNA LOR-1284 | - |
| dc.type | Article | - |
| dc.publisher.location | 그리이스 | - |
| dc.identifier.scopusid | 2-s2.0-84906319299 | - |
| dc.identifier.wosid | 000338780300039 | - |
| dc.identifier.bibliographicCitation | ANTICANCER RESEARCH, v.34, no.7, pp 3531 - 3535 | - |
| dc.citation.title | ANTICANCER RESEARCH | - |
| dc.citation.volume | 34 | - |
| dc.citation.number | 7 | - |
| dc.citation.startPage | 3531 | - |
| dc.citation.endPage | 3535 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Oncology | - |
| dc.relation.journalWebOfScienceCategory | Oncology | - |
| dc.subject.keywordPlus | OLIGONUCLEOTIDES | - |
| dc.subject.keywordPlus | NANOCARRIERS | - |
| dc.subject.keywordAuthor | Lipid nanoparticle | - |
| dc.subject.keywordAuthor | siRNA | - |
| dc.subject.keywordAuthor | proteinase K | - |
| dc.subject.keywordAuthor | cancer | - |
| dc.subject.keywordAuthor | ribonucleotide reductase | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
